Introduction
============

Cytomegalovirus (CMV) can sometimes affect the gastrointestinal (GI) tract, and the majority of such CMV infections have been reported in immunosuppressed patients ([@B1],[@B2]). The colorectum is the most frequently affected site in the GI tract. In contrast, CMV esophagitis is relatively infrequent ([@B2],[@B3]). The symptoms of CMV esophagitis include dysphagia, odynophagia, and epigastric pain, while massive bleeding followed by hypovolemic shock is rarely observed.

We herein report a patient with CMV esophagitis who presented with hematemesis after orthopedic surgery. In addition, the patient presented with hematemesis and hemodynamic failure due to CMV esophagitis. It is noteworthy that the patient did not show apparent immunosuppression, although diabetes and hypoalbuminemia might lead to relative immune dysfunction. This case underscores the fact that CMV esophagitis can occur in a diabetic patient with a poor nutritional status and cause massive bleeding.

Case Report
===========

A 49-year-old-man was referred to Kurashiki Central Hospital owing to chronic back pain and paresthesia caused by spondylolysis, lasting for several years. He had a history of diabetes and cerebral infarction. He had been taking clopidogrel, cyclooxygenase-2 inhibitor celecoxib, and oral hypoglycemic agents (i.e., metformin, empagliflozin, and sitagliptin). Preoperative testing was negative for human immunodeficiency virus.

He underwent interbody fusion surgery for the treatment of S4 spondylolysis. Since his diabetic condition was uncontrolled, his HbA1c value was 9.0%. He had undergone intensive insulin therapy for four weeks prior to the surgery that had gradually improved his blood sugar level; however, the value had remained at 8.4%. There was no diabetic nephropathy or retinopathy. After the surgery, his white blood cell (WBC) count and C-reactive protein (CRP) level temporarily increased, and the serum albumin level decreased rapidly ([Table 1](#t001){ref-type="table"}). We hypothesized that the systemic response to surgical injury to the spine had led to the inflammation and hypoalbuminemia because the WBC and CRP level normalized rapidly upon the administration of antibiotics until the day after the surgery, and only a low-grade fever remained. However, the patient complained of nausea after the surgery, and his food intake amount significantly decreased, necessitating peripheral intravenous nutrition. He started to consume a small amount of food on postoperative day (POD) 5. However, he experienced chest pain following the meal. Electrocardiogram and echocardiography examinations showed no abnormalities. Although a potassium-competitive acid blocker was administered on POD 7, this symptom did not resolve.

###### 

Progress of Laboratory Data.

                      Pre 7      POD2        POD5        POD7        POD10      POD13      POD15      POD35
  ----- -- ------- -- ------- -- -------- -- -------- -- -------- -- ------- -- ------- -- ------- -- -------
  Hb       g/dL       15.9       17.4        14.1        13.5        11.9       8.1        8.6        12
  Alb      g/dL       4.1        3.8         2.5         2.5         2.7        2.6        2.8        4.1
  BUN      mg/dL      13         26          17          10          20         6          4          14
  Cr       mg/dL      0.57       0.73        0.44        0.46        0.62       0.55       0.61       0.63
  WBC      /μL        7,000      27,800      13,100      11,800      9,100      7,700      6,800      7,600
  CRP      mg/dL      0.09       22.51       5.76        3.73        2.3        0.57       0.39       0.06
  FBS      mg/dL      \-         306         148         212         166        163        145        \-

Pre: preoperative day, POD: postoperative day, Hb: hemoglobin, Alb: albumin, BUN: blood urea nitrogen, Cr: creatinine, WBC: white blood cell count, CRP: C-reactive protein, FBS: fasting blood sugar

On POD 10, the patient suddenly vomited a large amount of fresh blood. His blood pressure and pulse rate were 77/43 mmHg and 120/min, respectively. Although computed tomography showed no bleeding site in the upper GI tract, blood clots were detected in the esophagus. Urgent esophagogastroduodenoscopy (EGD) also revealed an adherent blood clot occupying the esophagus ([Fig. 1a](#g001){ref-type="fig"}). After removal of the blood clots, multiple superficial ulcers affecting the entire circumference of the upper to distal esophagus were observed ([Fig. 1b](#g001){ref-type="fig"}). A red exposed vessel with oozing hemorrhaging was identified in the mid esophagus ([Fig. 2a](#g002){ref-type="fig"}). Although multiple punched-out ulcers existed in the duodenum, no site of bleeding was observed ([Fig. 1c](#g001){ref-type="fig"}). There was no mucosal damage in the stomach. Hemostasis for an exposed vessel was successfully achieved using hemoclips ([Fig. 2b](#g002){ref-type="fig"}). He restarted taking clopidogrel along with a liquid meal 2 days after the hemostasis, and no symptoms nor bleeding were observed thereafter.

![(a, b) An adherent blood clot occupying the esophagus and multiple superficial ulcers affecting the entire circumference of the upper to distal esophagus; (c) multiple superficial ulcers in the duodenum.](1349-7235-58-2949-g001){#g001}

![(a) A red exposed vessel with oozing hemorrhaging; (b) hemostasis of the exposed vessel was successfully achieved using hemoclips.](1349-7235-58-2949-g002){#g002}

EGD performed 15 days after surgery revealed incomplete healing of the multiple ulcers in the esophageal and duodenal mucosa ([Fig. 3](#g003){ref-type="fig"}). Biopsy specimens from the esophageal ulcer showed an ulcerated mucosa with inflammation and intranuclear inclusion bodies ([Fig. 4a](#g004){ref-type="fig"}). An immunohistochemical analysis revealed positivity for anti-CMV antibodies ([Fig. 4b](#g004){ref-type="fig"}), while the patient showed negative results for CMV antigenemia. Intranuclear inclusion bodies and positive staining results for anti-CMV antibodies were not observed in the biopsy specimens of the duodenum ulcer. Repeated EGD after the two-week administration of oral ganciclovir revealed that the mucosa of the esophagus and duodenum was healed ([Fig. 5](#g005){ref-type="fig"}). He had no symptoms of recurrence after a total of three weeks of ganciclovir administration.

![(a, b) Incompletely healed multiple ulcers in the esophagus; (c) incompletely healed ulcer in the duodenum.](1349-7235-58-2949-g003){#g003}

![Histological findings of biopsy specimens. (a) Intranuclear inclusion bodies in Hematoxylin and Eosin staining (arrow); (b) immunohistochemical staining showing cells positive for anti-CMV antibodies (arrows).](1349-7235-58-2949-g004){#g004}

![(a, b) The mucosa was healed from the upper to distal esophagus; (c) the duodenal mucosa was also healed.](1349-7235-58-2949-g005){#g005}

Discussion
==========

CMV is a species of the herpes virus and a common viral pathogen in humans. Serious infectious complications are induced either by reactivation of a latent CMV infection or by the acquisition of a primary CMV infection ([@B4]). Reactivation of CMV mainly occurs in immunosuppressed patients with various underlying diseases, such as concomitant immunodeficiency virus infection, transplant recipients who are taking immunosuppressive agents, those with malignant diseases and inflammatory bowel diseases, and patients undergoing chemotherapy or steroid treatment. Serious manifestations owing to CMV infection sometimes result in severe morbidity and mortality in affected patients ([@B1],[@B4]).

CMV infection is generally infrequent in immunocompetent patients. However, the numbers of case reports and case series describing CMV infection in immunocompetent patients have been increasing. Susana et al. reported that 25% (3/12) of patients with CMV infection in the GI tract were not immunodeficient or under immunosuppression treatment ([@B5]). Bonetti et al. reported that 50% (15/30) of the patients were apparently healthy individuals ([@B6]). We presumed that the patient in the present case was not severely immunosuppressed; however, we could not confirm this because we did not measure the CD4 and CD8 expression. Furthermore, uncontrolled diabetes and hypoalbuminemia might have caused immune dysfunction to some degree, leading to CMV infection in the esophagus. Some reports have indicated an association between CMV infection and diabetes mellitus ([@B7]-[@B9]). Lantini et al. noted that severe manifestations with CMV infection in an immunocompetent patient were partly associated with immune dysfunction, such as that observed in kidney disease or diabetes mellitus ([@B7]). Lee et al. reviewed reactivated CMV proctitis in an immunocompetent patient and reported that 54.5% (6/11) of patients with CMV proctitis had diabetes mellitus ([@B9]). The possible mechanisms underlying susceptibility to CMV in diabetes patients include hyperglycemia that causes damage to the neutrophil function, reduction of response to T cells, and dysfunction of humoral immunity ([@B10]). Previous studies regarding cell-mediated immunity reported that the T cell function was defective in poorly controlled type 1 diabetes patients ([@B11]). The complement system is associated with humoral immunity, and some studies have revealed a deficiency in the C4 component in diabetes ([@B12]). These deficiencies cause polymorphonuclear dysfunction and reduce the cytokine response. The B cell humoral immune response function is also affected by complement activation products. In addition, previous reports mentioned the association between hypoalbuminemia and CMV infection. Hypoalbuminemia revealed itself to be a significant risk factor for CMV infection in rheumatic disease and chronic lymphoproliferative diseases, such as in liver transplant recipients ([@B13]-[@B15]). Furthermore, Van et al. observed a decrease of CMV-specific immunoglobulin G and albumin levels in patients with CMV reactivation after renal transplantation ([@B16]). These findings indicate that CMV infection should be considered in the differential diagnosis, not only in apparently immunosuppressed patients but also in patients with relative immune dysfunction, such as those with diabetes and/or hypoalbuminemia.

Although the colorectum is the most common site of CMV infection in the GI tract, involvement of the upper GI tract, which leads to esophagitis, gastritis, duodenitis, gastric ulcer, or duodenal ulcer, has also been reported ([@B3]). The most common symptoms associated with CMV esophagitis are dysphagia, odynophagia, and epigastric pain ([@B17]). Hematemesis is a rare manifestation of CMV esophagitis, compared with CMV gastritis/duodenitis ([@B18],[@B19]). Hence, there have been few reports describing patients with CMV esophagitis who presented with hematemesis and/or hemodynamic failure.

To our knowledge, seven patients with CMV esophagitis showing hematemesis have been reported in the literature ([Table 2](#t002){ref-type="table"}) ([@B5],[@B19]-[@B24]). Five of the seven patients were under immunosuppression treatment and had been taking immunosuppressive agents such as steroids or cyclophosphamide. None of the patients had diabetes mellitus or hypoalbuminemia as far as we have searched. Among the seven patients, only three showed hemodynamic failure; all of them were immunosuppressed and had been taking immunosuppressive agents. Two patients required insertion of a Sengstaken-Blakemore tube, because the bleeding source could not be identified and the bleeding was uncontrollable. In the patient in the present case, although hemostasis was successfully achieved, it was difficult to detect the site of bleeding. In one patient in a previous study, a red exposed vessel was endoscopically treated using hemoclips ([@B24]), as in our case.

###### 

Summary of Published Cases of Cytomegalovirus Esophagitis with Hematemesis.

  Reference   Endoscopic features/disease location   Clinical presentation   Treatment              Hemodynamic failure   DIC   Immune-compromised state   Comorbidity                         Immuno- suppressive agents   Antithrombotic drug/ NSAIDs   Diagnosis                                                    Treatment   Outcome
  ----------- -------------------------------------- ----------------------- ---------------------- --------------------- ----- -------------------------- ----------------------------------- ---------------------------- ----------------------------- ------------------------------------------------------------ ----------- ----------------------
  \(5\)       deep ulcer/unknown                     hematemesis/ melena     unknown                no                    no    AIDs, DLBCL                                                    Immuno- suppressive agents   unknown                       intranuclear inclusions or immunostaining                    GCV+VGCV    alive
  \(19\)      multiple ulcer/middle esophagus        hematemesis             S-B tube →operation    yes                   yes   GPA                        achalasia                           PSL                          no                            surgical specimens: intranuclear inclusions/immunostaining   GCV         alive
  \(20\)      superficial ulcer/unknown              hematemesis             epinephrine/thrombin   yes                   no    SLE                                                            PSL, cyclophosphamide        unknown                       biopsy: immunostaining                                       GCV         alive
  \(21\)      blackish discoloration/unknown         hematemesis/ melena     none                   no                    no    no                         alcoholism                          none                         no                            biopsy: intranuclear inclusions                              none        alive
  \(22\)      superficial ulcer/lower esophagus      hematemesis             unknown                no                    no    no                         acute pancreatitis following ERCP   none                         no                            biopsy: immunostaining                                       GCV         death (pancreatitis)
  \(23\)      severe ulcer/lower esophagus           hematemesis             S-B tube               no                    yes   endstage renal failure     liver cirrhosis                     PSL                          no                            autopsy: intranuclear inclusions                             none        death (DIC)
  \(24\)      superficial ulcer/middle esophagus     hematemesis             clipping               yes                   no    MPA                                                            PSL, cyclophosphamide        no                            biopsy: intranuclear inclusions/immunostaining               GCV         death (pneumonia)

GPA: granulomatosis with polyangiitis, MPA: microscopic polyangiitis, SLE: systemic lupus erythematosus, AIDs: acquired immunodeficiency syndrome, DLBCL: diffuse large B-cell lymphoma, PSL: prednisolone, GCV: ganciclovir, VGCV: valganciclovir, S-B tube: Sengstaken--Blakemore tube, DIC: disseminated intravascular coagulation, NSAIDs: non-steroidal anti-inflammatory drug

Representative endoscopic features of CMV infection in the upper GI tract include deep, punched-out ulcers. However, endoscopic features of previously reported CMV esophagitis are often nonspecific, including solitary or multiple deep ulcers and superficial ulcers, as shown in [Table 2](#t002){ref-type="table"}. The present patient also showed multiple superficial ulcers affecting the entire circumference of the upper to distal esophagus, which necessitated a differential diagnosis from other diseases, such as acute esophageal mucosal lesion, acute esophageal necrosis (AEN), and non-steroidal anti-inflammatory drug-induced ulcer ([@B25],[@B26]). In fact, this patient had been taking clopidogrel and celecoxib, which can also cause mucosal disorders and severe bleeding ([@B27],[@B28]). There has been only one case report describing AEN with CMV infection after renal transplantation ([@B29]). Although the pathogenesis of AEN remains unclear, it is considered that the temporary reduction of esophageal blood perfusion and acid reflux cause AEN. In the present case, we considered CMV infection to be the principal cause of esophagitis, as the esophageal ulcers were improved after the administration of the anti-CMV drug. However, it is quite possible that other factors contributed to the pathogenesis of the esophageal ulcer, such as hyperglycemia, hypovolemia, hypoalbuminemia, acid reflux, antiplatelet drugs, and NSAIDs.

The gold standard for the diagnosis of CMV infection in the GI tract is a histopathology analysis with immunohistochemical staining ([@B30]). The current patient and all previously reported patients, except for one, were diagnosed based on the results of histopathological examinations. However, histology has a low sensitivity, so CMV infection may be missed ([@B31]). In the present patient, although CMV was not detected in the duodenum, the duodenal ulcer might have been caused by a CMV infection as well, as it presented with a punched-out ulcer ([Fig. 4C](#g004){ref-type="fig"}).

Anti-CMV drugs, such as ganciclovir and valganciclovir, were used in all cases. Lim et al. suggested that these drugs were important for preventing rebleeding from CMV-related lesions in the GI tract ([@B32]). Three of the seven patients died after bleeding due to disseminated intravascular coagulation, pneumonia, and/or progressive complications of pancreatitis. Although this lethal outcome was more likely to be associated with their immunosuppressed condition than with CMV esophagitis, the bleeding event obviously worsened their condition.

In conclusion, CMV esophagitis can occur not only in immunosuppressed patients but also in those with relative immune dysfunction caused by diabetes and hypoalbuminemia. Furthermore, although rare, CMV may cause massive bleeding, leading to hemodynamic failure. Physicians should therefore consider CMV esophagitis in the differential diagnosis of esophageal bleeding of unknown cause, even in patients without apparent immunodeficiency. A prompt histopathological diagnosis and administration of anti-CMV drugs are essential for management of CMV esophagitis.
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